Exozymes closes $639,990 unit offering to one investor, with warrants at $11.24
Exozymes sold 71,110 shares and 35,555 warrants to one investor on June 30, 2026, for gross proceeds of $639,990 before about $74,799 in commissions and other expenses. The company says net proceeds will fund its NCT business and products, next-in-line products, research and development, and general corporate purposes. The warrants include a reset to $0.001 if the company sells shares below $8.99 before June 5, 2027, which could dilute existing holders.
Key points
- Gross proceeds of $639,990, with commissions of $44,799 and other expenses of approximately $30,000
- Each $18.00 unit included one share valued at $8.99 and one warrant valued at $0.02
- Warrants are exercisable at $11.24 from June 5, 2027, to June 5, 2031, and reset to $0.001 on certain lower-priced sales before June 5, 2027
- MDB Capital, the placement agent, received a warrant to buy 10,666 shares at $11.24
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.